Methadone-based Multimodal Analgesia Provides the Best-in-class Acute Surgical Pain Control and Functional Outcomes With Lower Opioid Use Following Major Posterior Fusion Surgery in Adolescents With Idiopathic Scoliosis by Ye, Jian et al.
1
Issue 4 • Volume 5
Methadone-based Multimodal Analgesia Provides 
the Best-in-class Acute Surgical Pain Control 
and Functional Outcomes With Lower Opioid 
Use Following Major Posterior Fusion Surgery in 
Adolescents With Idiopathic Scoliosis
Jian Ye, MD*; Karen Myung, MD, PhD, MBA†; Senthil Packiasabapathy, MD*; Jeffrey S. Yu, MD‡; 
Joseph E. Jacobson, MD†; Stephanie C. Whittaker, MSN, RN-BC, PCNS-BC*;  
Peter Castelluccio§; Meghan Drayton Jackson DO, FAAP, MBOE, CPPS¶;  
Senthilkumar Sadhasivam, MD, MPH, MBA*     
INTRODUCTION
Posterior spinal fusion (PSF) for adoles-
cent idiopathic scoliosis is often excru-
ciatingly painful procedure.1 Many 
adolescents have heightened pain per-
ception due to their immature emotional 
state.2 Inadequate management of acute 
postoperative pain can delay functional 
recovery and prolong the length of hospital 
stay (LOS). It can also lead to chronic persistent 
postsurgical pain (36% prevalence) and prolonged 
opioid use (10% prevalence) after PSF.3,4
Many postoperative analgesic strategies are available 
for patients undergoing PSF, but no single modality has 
been superior. Patient-controlled analgesia (PCA) with 
intravenous (IV) opioids has been standard in many cen-
ters, but opioids have undesirable side effects, including 
respiratory depression. Epidural or intrathecal adminis-
tration of local anesthetics have opioid-sparing analge-
sia.5–8 Unfortunately, epidural analgesia has a high failure 
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rate and can interfere with postoperative neurologic eval-
uation. Intrathecal morphine is associated with urinary 
retention, itching, and, rarely, respiratory depression.
There is a growing body of literature to support the 
intraoperative use of methadone—a long-acting opioid.9 
Methadone is efficacious for complex spine surgery in 
adults.10,11 Some studies suggest postoperative respira-
tory monitoring is prudent due to high incidence (36.8%) 
of respiratory depression when used with PCA hydro-
morphone.12 However, there is limited evidence for the 
effectiveness and safety of perioperative methadone in 
children. Methadone has been effective for postoperative 
pain in younger children and those undergoing Nuss pro-
cedure for surgical correction of pectus excavatum.13,14 
There is only limited evidence of methadone for PSF is 
available in children. In a randomized control study of 
60 adolescents undergoing PSF, intraoperative methadone 
decreased intraoperative opioid requirements.15 In a small 
study of 31 adolescents that received a single relatively 
larger dose of intraoperative methadone (0.1–0.3 mg/kg; 
maximum 20 mg), there was no reduction in postopera-
tive opioid consumption.16 This result could be related to 
the relatively shorter half-life of methadone in children 
compared with adults.17 Moreover, a single larger dose of 
intraoperative methadone in adolescents had a high inci-
dence of respiratory depression after PSF.12 A single dose 
of intraoperative methadone, as part of a multimodal 
analgesia regimen, improved pain scores with modest 
shortening in LOS without significant reduction in opioid 
consumption on POD 1 and 2.18
Multimodal analgesia with opioids, nonopioid analge-
sics, and muscle relaxants reduce opioid usage, minimize 
opioid-related side effects, facilitate the transition from 
IV to oral administration, and permit earlier hospital dis-
charge.18–21 Muscle spasm contributes to a significant 
amount of pain after PSF. Methocarbamol, in particular, has 
been proven to be safe and effective for acute lower back 
pain.22–24 Nonsteroidal anti-inflammatory drugs (NSAIDs) 
are safe and effective in pediatric orthopedic surgery.25–27 
Acetaminophen is a centrally acting cyclo-oxygenase inhibi-
tor and an effective opioid-sparing analgesic in children.28,29
We hypothesized that a multimodal analgesia regi-
men, including multiple and small doses of methadone 
and nonopioid analgesics and adjuncts, would promote 
earlier hospital discharge, improve pain scores, and lower 
opioid consumption in adolescents undergoing PSF.
METHODS
Context
We performed this quality improvement initiative at the 
Riley Hospital for Children, a tertiary care hospital. Before 
implementing the new protocol, all PSF patients received 
intrathecal morphine and postoperative morphine PCA 
with the median LOS of 3 to 4 days. We implemented 
the new Acute Pain Service (APS) protocol (Table 1) in 
September 2017 to enhance recovery and decreasing LOS. 
The decision was made a priori to collect outcome data, 
including LOS, pain scores, opioid consumption, and opi-
oid-related adverse effects.
Design
We analyzed outcomes using a retrospective matched cohort 
design after approval by the institutional review board (with 
waived informed consent.) We compared the APS inter-
vention cohort with the historical matched controls who 
received PSF before protocol implementation. All subjects 
were operated on by the same pediatric spine surgeon.
Enrollment criteria
The baseline period (November 2012 to August 2017) 
included 102 patients who had PSF; we selected 61 
matched patients. The intervention (APS protocol) period 
(September 2017 to January 2019) included 72 PSF 
patients; however, only 61 patients received methadone and 
the full interventions due to drug shortages. We matched 
patients on age, sex, and the number of vertebral levels 
fused (Table  2) since these factors contribute to overall 
opioid usage.3 A single pediatric spine surgeon performed 
all procedures. We excluded subjects with neuromuscular 
scoliosis, congenital QT prolongation, and allergy to any 
of the protocol drugs (ketorolac, methocarbamol, metha-
done, or acetaminophen) during the intervention period.
Standardized anesthesia management
Anesthesia management was consistent during the study. 
We standardized the intraoperative anesthesia technique 
for both groups. After induction and endotracheal intu-
bation, we obtained venous access and arterial line. The 
patients were placed on total IV anesthesia with propofol 
(75–200 µg/kg/min), remifentanil (0.1–0.5 µg/kg/min), 
and ketamine (0.25–1 mg/kg/h) to facilitate intraopera-
tive neuromonitoring.
Baseline period analgesia management
Before the protocol was implemented, the patients were 
given intrathecal morphine by the surgeon at a dose of 5 µg/kg 
Table 1. Acue Pain Service (APS) Intervention Protocol
Scheduled PRN
PreOp
PO acetaminophen 1 dose  
PO methadone 1 dose  
POD0 IV Methocarbamol Q8H X 6 IV morphine/
hydromorphone Q3H
 IV ketorolac Q6H X 7 doses PO Diazepam Q6H
 IV Ondansetron Q8H x 5 doses IV Nalbuphine Q6H
 PO methadone Q12H X 3 doses
PO Acetaminophen Q6H
Scopolamine patch 72H
POD1 PO oxycodone Q6H IV morphine / 
hydromorphone Q3H
PO naloxegol QD PO diazepam Q6H
 IV nalbuphine Q6H
POD2 PO ibuprofen Q6H PO ondansetron Q6H
PO methocarbamol Q8H SC methylnaltrexone
PRN, Pro Re Nata (as needed);
QTc, corrected QT;
PACU, Post-Anesthesia Recovery Unit.
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intraoperatively. Postoperatively, they were placed on 
oral gabapentin (100 mg per dose) 3 times a day. They 
received a morphine PCA on POD0 and transitioned 
to oxycodone or hydrocodone on POD1 with IV mor-
phine as needed for breakthrough pain. Patients received 
ketorolac, acetaminophen, and diazepam as needed.
Intervention period analgesia management  
(APS protocol)
The APS protocol (Table 1) was developed based on evi-
dence,9–11,15,16,18 and the authors’ clinical expertise using 
multiple small doses of methadone and multimodal 
analgesia in adolescents undergoing major inpatient sur-
gery. Preoperatively, patients received oral acetamino-
phen (15 mg/kg, maximum 650 mg). As this multimodal 
protocol with scheduled ondansetron was new at our 
institution, we obtained an electrocardiogram (ECG) pre-
operatively in the orthopedic clinic to screen for baseline 
QT prolongation.
Intraoperatively, the APS group received a small dose 
of IV methadone (0.1 mg/kg, maximum 5 mg). Single 
intraoperative doses (0.1–0.3 mg/kg) in adolescents have 
a higher incidence of adverse effects and lack of sustained 
analgesia.16 We used a small dose of methadone (0.1 mg/
kg, maximum 5 mg doses) intraoperatively and repeated 
every 12 hours until discharge to minimize adverse effects 
and sustain analgesia.
Postoperatively, patients received 3 more doses of 
methadone (0.1 mg/kg, maximum of 5 mg) every 12 hours 
starting on the evening of the day of surgery (POD0). An 
ECG was obtained on POD1 to verify that there was no 
significant QT prolongation (> 460 ms). Methocarbamol 
was given every 8 hours with the first dose given in the 
post-anesthesia recovery unit. Ketorolac was scheduled 
for the first 3 days every 6 hours, with the first dose given 
at 8:00 PM on POD0 (or immediately after surgery if 
before 2:00 PM). On POD2, we stopped ketorolac and 
started ibuprofen before discharge. We started oral acet-
aminophen every 6 hours, starting on POD1. We used 
IV hydromorphone as needed for breakthrough pain. 
Patients did not receive PCA opioids. Patients received 
oral oxycodone on POD 1 around noon when tolerat-
ing oral diet. Patients received scheduled ondansetron 
every 8 hours for the first 48 hours after surgery as well 
as scheduled naloxegol, a peripherally acting μ-opioid 
receptor antagonist, to prevent opioid-induced constipa-
tion (Table 1).
Postoperatively, the APS team managed acute surgical 
pain by placing all analgesic orders and assessing patients 
daily. Before discharge, the APS team performed medi-
cation management education with the patient, parents, 
and nursing staff. Per Indiana state regulations, patients 
received the opioid prescription for 7 days postdischarge.
Bowel Regimen
Postoperative constipation or ileus is a common problem 
in the scoliosis population, both due to the nature of the 
surgery and the frequent use of opioids. The bowel regi-
men was unchanged between the baseline and the inter-
vention period, and it included polyethylene glycol (17 g) 
per day, starting 5 days preoperatively and continuing 
after surgery. On the morning of POD1, patients received 
a glycerin suppository and a dose of magnesium hydrox-
ide. Patients who had no bowel movement by the eve-
ning of POD1 received an enema. During the intervention 
period, patients received additional oral Naloxegol.30
Physical Therapy
During the baseline and intervention periods, all patients 
received similar postoperative standardized physical ther-
apy (PT) and rehabilitation measures, including getting 
out of bed and room with assistance.
Discharge Readiness
Hospital discharge criteria for both groups included: (1) 
able to take oral food, including oral analgesics without 
nausea/vomiting; (2) pain controlled by oral analgesics; 
(3) regular bowel movements; (4) ambulation with mini-
mal help and without significant pain; and (5) no surgical 
complications (eg, bleeding, wound infection).
Outcome Measures
The primary outcome was time to hospital discharge 
(days). Secondary outcomes included opioid consumption 
(in morphine milligram equivalents [MME]) on each post-
operative day and in total, pain scores (taken on a 0–10 
Numerical Rating Scale for pain and averaged over each 
postoperative day), opioid-related side effects (measured 
by time to first bowel movement, as constipation is a sig-
nificant issue), and postdischarge pain-related phone calls.
Table 2. Demographics
Characteristic Baseline–Control Group (n = 61) Methadone-Based Multimodal Analgesia (n = 61) P
Age (y) 13.8 (12.8, 15.6) 13.9 (12.7, 15.5) 0.92
Sex: Female 51 (83.6%) 51 (83.6%) 1.00*
Body mass index (kg/m2) 20.5 (19.1, 25.6) 20.3 (18.0, 24.1) 0.35
Preoperative major Cobb (degrees) 57 (53, 68) 61 (55, 67) 0.29
Number of levels fused 13 (11, 13) 12 (11, 13) 0.80
Number of osteotomies 6 (4, 8) 7 (6, 9) <0.001
Either median (25th, 75th percentiles) or count (percentage).
*Chi-square test.
All other P values using Wilcoxon rank-sum tests.
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Statistical Analysis
We used QI Macros for Excel Version 2019.06 to statisti-
cally analyze the impact of our intervention on LOS (Fig. 
1) and total MME (Fig. 2). The LOS is displayed in a run 
chart, and the total MME is displayed in an X-chart. We 
compared categorical variables using the Chi-square test. 
We used the Wilcoxon rank-sum test for comparison of 
medians. We used a mixed model for repeated measures 
for comparing means of normally distributed variables 
and adjusted for multiple testing via Sidak correction.
RESULTS
We included a total of 122 patients—61 patients in 
the baseline period and 61 in the intervention period 
(Table 2). One notable change in the APS protocol, imme-
diately after implementation, was the removal of prega-
balin administration. We initially included pregabalin 
in the regimen due to its neuromodulating properties,31 
and stopped its use after the first 3 patients due to signif-
icant urinary retention observed in these patients. Other 
minor changes included switching from IV methadone to 
oral (and back to IV), and switching to granisetron from 
ondansetron for a short while due to drug shortages.
Primary Outcome
Patients treated with the APS protocol had significantly 
shorter hospital stays than patients in the baseline period 
(Table 3, Figure 1). The median length of stay was 2 days. 
Most patients discharged essentially on POD2 AM, with 
some on POD1 PM—a decrease from the baseline median 
of 3 days (Fig. 1) (P < 0.001).
Secondary Outcomes
The mean opioid usage (MME) (29.3 vs 9.9 mg) for 
patients in the intervention period was higher on POD0 
compared with the control group (P < 0.001, Table  3, 
likely due to earlier ambulation and the higher sched-
uled dosing of opioids on the APS protocol. Mean opioid 
consumption was similar on POD1 for the 2 groups, but 
50% lower for the APS group than the control group on 
POD2 (21.5 vs 44.4 mg; P < 0.001). Total opioid con-
sumption was approximately 30% lower for the APS 
group (mean of 98 mg in the APS group vs 128 mg in the 
control group; P < 0.001). In Figure 2, the wider control 
limits in the baseline period highlight that the process had 
a lot of variation, including 2 patients that were outliers. 
The total MME was already trending down before the 
new protocol implementation, and the intervention added 
to that decline. The control limits narrowed significantly, 
indicating less variability and more reliability in the pro-
cess for similar outcomes.
The mean pain scores were higher in the APS group 
than controls on POD0 (4.3 vs 2.9; P < 0.001; Table 3), 
likely due to earlier ambulation in the APS group and/or 
the beneficial effects of intrathecal morphine in the con-
trol group. Pain scores were similar on POD1 and lower 
on POD2 for the APS group (mean 3.2 vs 4.2 for the con-
trol group; P = 0.001). The overall trend showed decreas-
ing pain scores in the APS protocol group and increasing 
pain scores in the control group over the first 3 days after 
surgery before discharge.
The median time to first bowel movement was signifi-
cantly shorter in the APS group compared with the con-
trol group (1 day vs 2 days; P < 0.001). The number of 
postdischarge pain-related phone calls was significantly 
less in the APS intervention period compared with the 
baseline period (P < 0.006; Table 3).
Adverse Effects
No significant opioid-related adverse effects (especially 
respiratory depression) were observed in the APS group. 
The first postoperative bowel movement was achieved 1 
day earlier during the intervention period (Table 3). The 
Table 3. Results of Implementing Multimodal Analgesia Protocol in Idiopathic Scoliosis Patients Undergoing Spinal 
Fusion Surgery
Outcome Baseline–Control Group (n = 61) Methadone-Based Multimodal Analgesia (n = 61) P
Length of stay (days) 3 (3, 4) 2 (2, 2) <0.001*
Pain scores
 POD 0 2.9 ± 2.0 4.3 ± 1.5 <0.001
 POD 1 3.9 ± 1.4 3.7 ± 1.5 0.97
 POD 2 4.2 ± 1.3 3.2 ± 1.4 0.001
 POD 3 3.9 ± 1.5 2.9 ± 1.9 <0.001
Opioid use
 POD 0 9.9 ± 9.2 29.3 ± 7.9 <0.001
 POD 1 41.4 ± 23.3 45.8 ± 10.7 0.55
 POD 2 44.4 ± 18.8 21.5 ± 7.9 <0.001
 POD 3 33.2 ± 19.9 14.5 ± 8.8 <0.001
Total 127.5 (98.3, 171.4) 98.1 (87.9, 113.5) <0.001*
Time to first bowel movement (d) 2 (2, 3) 1 (1, 1) <0.001*
Postdischarge pain calls (n) 0 (0, 1) 0 (0, 0) 0.006*
Either mean ± SD or median (25th, 75th percentiles).
*Wilcoxon rank-sum P values.
All other P values from Mixed Model for Repeated Measures (MMRM), adjusted for multiple testing via Sidak correction.
Opioid usage in MME (MME, Morphine Milligram Equivalents: 1 mg of methadone = 3 MME, 1 mg of hydromorphone = 4 MME, 1 mg of oral 
oxycodone = 1.5 MME, 1 mg oral hydrocodone = 1 MME).
POD, postoperative day.
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mean corrected QT interval increased from baseline to 
POD1 (416–431 ms), remaining within normal limits (< 
440 ms).
DISCUSSION
New methadone-based multimodal analgesic protocol 
significantly enhanced the recovery from PSF for patients 
with idiopathic scoliosis. Methadone-based multimodal 
analgesia significantly reduced hospital stays, postopera-
tive pain scores, total opioid consumption, and opioid-as-
sociated side effects, including constipation. The median 
LOS in our study population (2 days) was significantly 
shorter than the national average for PSF and most of the 
published studies on multimodal analgesia protocols.18,32 
This observation is particularly significant in reducing the 
cost of care in a value-based model and reducing poten-
tial risks for hospital-acquired infections following major 
spinal instrumentation. This shorter hospitalization 
translates to at least $10,000 health care cost savings per 
patient in 2020 U.S. dollars.
In our protocol, we chose lower intraoperative doses of 
methadone to avoid adverse effects reported with higher 
doses in adults and children. We also dosed methadone 
every 12 hours to compensate for rapid clearance in chil-
dren, sustain the analgesic effects, and decrease the neces-
sity for short-acting opioids. We were able to significantly 
lower overall opioid use, pain scores, and opioid-related 
adverse effects while achieving early ambulation and 
the shortest reported LOS following spine fusions. In all 
study patients receiving the lower dose of methadone, 
routine ECGs revealed no significant QT prolongation or 
arrhythmias requiring intervention. We will discontinue 
routine ECGs to reduce costs further if methadone does 
not prolong corrected QT significantly in a larger cohort.
During the implementation of the protocol, we also 
noted other subjective improvements, including earlier 
mobilization from bed to chair, more productive PT ses-
sions, and a better overall sense of patient comfort and 
well-being without grogginess. Given the heavy pain 
burden these surgeries impose on adolescents even years 
later,33 there is certainly benefit in giving them a more 
pleasant perioperative experience.
It is important to note that this was also a multidisci-
plinary effort between the orthopedic and the anesthesia 
acute pain service. A dedicated pediatric acute pain service 
is highly valuable,34 but it is frequently difficult to imple-
ment—even in the setting of large pediatric hospitals.35 
The constant presence of the pain service has reassured 
patients and their families, improved inpatient acute pain 
management, and pain management after discharge due 
to the education on the discharge medication calendar.
Our experience with the methadone-based standard-
ized multimodal analgesia protocol for idiopathic sco-
liosis surgery led us to implement similar protocols 
in children undergoing other painful procedures such 
as pectus excavatum repair, with similar benefits. Our 
patients have fared so well on the methadone-based mul-
timodal analgesia protocol that we have discussed a goal 
of routine POD1 discharge following major spine fusions 
in adolescents with idiopathic scoliosis. Several patients 
in the methadone-based protocol group, about 25%, 
Fig. 1. Length of hospital stay (LOS) time series run chart. The run chart illustrates patients treated with the APS protocol during the 
intervention period had shorter hospital stays than patients in the baseline period. The median length of stay was 2 days during the 
intervention period, a decrease from the baseline median of 3 days.
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were discharged home the day after spinal fusion sur-
gery (POD1). Achieving POD1 discharge for the average 
patient would drastically change the landscape of adoles-
cent scoliosis surgery, leading to substantial cost savings, 
about $10,000 per patient.
Methadone itself is less expensive compared with the 
opioid PCA. Acquisition cost of PCA hydromorphone 
syringe (75 mcg/mL × 30 mL syringe) is $18, while metha-
done 5 mg is $1.58 (>10-fold cheaper). Typical pharmacy 
charges are about 10-fold higher than the acquisition 
costs. Some institutions add a charge for the use of the 
PCA pump ($200–500 per patient). Our research will 
enable institutions to provide cost-effective and safe 
pediatric-enhanced surgical recovery protocols for val-
ue-based care under bundled payments.
The new protocol also reduced opioid use and low-
ered postoperative pain scores. We are following PSF 
patients for chronic persistent pain and long-term opioid 
use. Effective management of acute postoperative pain 
and use of ketamine and methadone perioperatively had 
decreased incidence of persistent surgical pain to about 
5% in the last 2 years. This finding is substantially less 
than the 36% incidence reported in adolescents receiv-
ing nonmethadone-based multimodal acute postoperative 
pain management.36 This result is significant as we face a 
national opioid epidemic.
There are a few limitations to our study. It was a retro-
spective chart review with limited data on subjective mea-
sures such as patient satisfaction and physical mobility. 
However, the feedback from physical therapists and inpa-
tient nursing staff has been consistently positive in terms 
of patients’ comfort, cooperation, and early ambulation 
without drowsiness (frequently observed with the previous 
pain regimen). Another limitation is that the APS analgesic 
protocol had minor changes during implementation due to 
drug shortages (eg, IV ondansetron in place of IV granise-
tron, oral methadone in place of IV methadone for a brief 
duration). The oral bioavailability of methadone is 86%, 
and it is considered interchangeable with IV methadone. 
One of the more noteworthy modifications was removing 
pregabalin from the protocol—almost immediately after 
its implementation. Due to the evidence supporting the use 
of neuromodulators in the setting of postoperative pain 
for spine surgery,31 pregabalin had been part of the pro-
tocol initially. However, we experienced significant post-
operative urinary retention in 3 patients with pregabalin, 
which resolved once we stopped it.
Although we matched for known variables (age, sex, sur-
geon, and the number of laminectomies), there is potential 
for sampling bias secondary to our effort to match cases 
individually. Due to the study design, temporal changes 
may have occurred over time. We made efforts to generalize 
all other aspects of patient management (standardization 
Fig. 2. Postoperative opioid use—X chart. The mean postoperative opioid usage in terms of Morphine Milligram Equivalents ((MME) 
is plotted. The upper (UCL) and lower (LCL) control limits are the 3 standard deviations from the mean. The wider control limits in the 
baseline period highlight that the process had a lot of variation, including 2 patients that were outliers outside of the UCL. The total 
MME was trending down just before the new protocol implementation as we developed the new standardized protocol. The new 
protocol intervention added to that decline and, most significantly, the control limits narrowed, indicating less variability and more 
reliability in the process for similar outcomes.
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of anesthesia, surgical management, and PT). Before the 
protocol implementation, we examined discharge data to 
screen for random fluctuation and eventual regression to 
mean after implementation. Large prospective multicenter 
trials are needed to validate our findings externally.
CONCLUSIONS
In conclusion, a new multimodal analgesic protocol fol-
lowing posterior spinal fusion surgery led to significantly 
reduced LOS, improved inpatient postoperative pain 
control, lower total opioid consumption, and opioid-re-
lated adverse effects following posterior spine fusion 
in adolescents with idiopathic scoliosis. Implementing 
this methadone-based multimodal analgesia protocol in 
other institutions may allow for enhanced recovery in 
children following this extremely painful surgery while 
lowering hospitalization costs and reducing opioid use. 
The protocol may lower the potential for opioid-associ-
ated adverse effects, including persistent opioid use and 
possibly reduce the incidence of persistent surgical pain. 
To replicate and externally validate this protocol in other 
centers, we need a large multicenter study in PSF for more 
complicated neuromuscular spines. We are currently eval-
uating the protocol for adolescents undergoing Nuss bar 
repairs for pectus excavatum, in addition to a continuous 
thoracic epidural analgesia.
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